ProQinase GmbH Partners with Cell Signaling Technology, Inc. to Co-Promote and Distribute Kinase Assays and Enzymes to the Drug
Freiburg an Beverly. ProQinase GmbH of Freiburg, Germany announces that it has entered into a distribution and co-marketing agreement with Cell Signaling Technology, Inc. of Beverly, MA, USA (CST). Under this exclusive alliance, CST will distribute the full line of ProQinase purified enzymes (76 kinases currently) on a scale for high-throughput screening and research, as well as in fully configured and validated kinase assays for the drug discovery market.
The integration of ProQinase's high quality enzymes with CST's premier phospho-specific antibody reagents will create value-added assay systems that will facilitate kinase inhibitor drug discovery, lead optimization and profiling.
There are over five hundred human protein kinases that transduce signals via protein phosphorylation and are critical regulators of innumerable cellular processes. A significant number of kinases have been implicated in human diseases, including cancer, inflammatory, metabolic and cardiovascular diseases. This has made protein kinases a major focus for pharmaceutical drug discovery. Successful kinase drug discovery requires validated and optimized reagents for target discovery and validation, high throughput screening (HTS) and therapeutic development. Critical reagents for this effort are high affinity phospho-specific antibodies and active, purified kinase enzymes for HTS drug discovery and lead compound specificity profiling.
"Cell Signaling Technology is decidedly the best partner for ProQinase " said Christoph Sachsenmaier, ProQinase's Head of Business Development. "We are very excited about this partnership and strongly believe that CST´s renowned expertise in antibody development and ProQinase´s strength in producing large quantities of highly active kinase enzymes will strongly impact the drug discovery and research market. Through this partnership we will be able to serve our customers faster and with a more comprehensive product portfolio".
"We are excited about joining forces with ProQinase to develop valuable solutions for kinase drug discovery", added Christopher Bunker, CST's Director of Business Development. "ProQinase has the reputation for superior kinase products and services that is an ideal fit with Cell Signaling Technology's expertise and market leadership in phospho-specific antibodies. Our combined high performance reagents will enable research and drug discovery scientists to more rapidly discover and develop important new kinase inhibitors leading to targeted therapeutic treatments for a range of human diseases."
Other news from the department business & finance
These products might interest you
Micro-Dx™ CE IVD by Molzym
Fully automated from sample to PCR analysis
Rapid identification of bacteria and fungi without time-consuming cultivation
DNA-free Taq Polymerases and Mastermixes by Molzym
DNA-free reagents for unrivalled sensitivity in molecular biology
Purity that makes the difference
DNA/RNA Shield™ SafeCollect Collection Kits by Zymo Research
Sample collection devices for simple & safe at-home testing
Best user experience for secure self-collection
Recombumin® Elite by Sartorius
ICHQ7 cGMP-compliant albumin for biotechnological applications
Increase consistency and safety for gene therapies and vaccines
CellGenix® Growth Factors and Cytokines by Sartorius
Recombinant growth factors without animal products
Optimised cell culture for T cells and MSCs in gene therapy
Greener Alternative Products by Merck Life Science
Sustainable laboratory products for environmentally conscious research
Over 2,500 ecological alternatives to reduce your laboratory footprint
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
MyCartis Announces Appointment of Dr. Jan Groen to its Board of Directors
Clavis Pharma receives US Orphan Drug Designation for CP-4126 to treat pancreatic cancer
Nuevolution A/S - Kopenhagen, Denmark
Amgen Announces FDA Licensure of Two New Manufacturing Facilities - Company Continues to Meet Increased Demand for Its Novel Therapeutics
Drug-induced cellular membrane complexes induce cancer cell death - New sub-cellular complex discovered
Fraunhofer-Institut für Biomedizinische Technik (IBMT) - Potsdam, Germany
DIREVO and Pfizer collaborate on therapeutic proteases
Sun Pharma to acquire Pola Pharma
Domainex appoints Timo Veromaa as Executive Chairman
Thyroid tumour: it takes two to tango
